BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 19861722)

  • 1. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
    Underwood CR; Garibay P; Knudsen LB; Hastrup S; Peters GH; Rudolph R; Reedtz-Runge S
    J Biol Chem; 2010 Jan; 285(1):723-30. PubMed ID: 19861722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
    Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
    Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
    Runge S; Thøgersen H; Madsen K; Lau J; Rudolph R
    J Biol Chem; 2008 Apr; 283(17):11340-7. PubMed ID: 18287102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
    López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
    J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
    West GM; Willard FS; Sloop KW; Showalter AD; Pascal BD; Griffin PR
    PLoS One; 2014; 9(9):e105683. PubMed ID: 25180755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
    Al-Sabah S; Donnelly D
    Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for ligand recognition of incretin receptors.
    Underwood CR; Parthier C; Reedtz-Runge S
    Vitam Horm; 2010; 84():251-78. PubMed ID: 21094903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Yang D; de Graaf C; Yang L; Song G; Dai A; Cai X; Feng Y; Reedtz-Runge S; Hanson MA; Yang H; Jiang H; Stevens RC; Wang MW
    J Biol Chem; 2016 Jun; 291(25):12991-3004. PubMed ID: 27059958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.
    Moon MJ; Lee YN; Park S; Reyes-Alcaraz A; Hwang JI; Millar RP; Choe H; Seong JY
    J Biol Chem; 2015 Feb; 290(9):5696-706. PubMed ID: 25561730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
    Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
    Graziano MP; Hey PJ; Strader CD
    Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
    J Biol Chem; 2012 Feb; 287(6):3642-58. PubMed ID: 22147710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function.
    Van Eyll B; Göke B; Wilmen A; Göke R
    Peptides; 1996; 17(4):565-70. PubMed ID: 8804062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
    Oddo A; Mortensen S; Thøgersen H; De Maria L; Hennen S; McGuire JN; Kofoed J; Linderoth L; Reedtz-Runge S
    Biochemistry; 2018 Jul; 57(28):4148-4154. PubMed ID: 29877701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity.
    Wilmen A; Göke B; Göke R
    FEBS Lett; 1996 Nov; 398(1):43-7. PubMed ID: 8946950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
    Moon MJ; Kim HY; Park S; Kim DK; Cho EB; Park CR; You DJ; Hwang JI; Kim K; Choe H; Seong JY
    J Biol Chem; 2012 Feb; 287(6):3873-84. PubMed ID: 22105074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
    Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
    J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.
    Runge S; Wulff BS; Madsen K; Bräuner-Osborne H; Knudsen LB
    Br J Pharmacol; 2003 Mar; 138(5):787-94. PubMed ID: 12642379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.